A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Trial Profile

A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Lipase (Primary)
  • Indications Exocrine pancreatic insufficiency; Pancreatitis
  • Focus Adverse reactions
  • Acronyms MS1819-SD
  • Most Recent Events

    • 27 Sep 2017 Data from the first six treated patients presented in an AzurRx BioPharma Media Release.
    • 23 Aug 2017 According to an AzurRx BioPharma media release, to further support enrollment in this trial and other planned future trials, company has added an additional clinical site in Australia.
    • 23 Aug 2017 According to an AzurRx BioPharma media release, 6th patient has been enrolled and results from these first six patients are expected in September 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top